Addition of Lenalidomide to R-CHOP May Improve Outcomes in Patients With Non-GCB DLBCL

CHICAGO—Addition of the immunomodulatory agent lenalidomide to R-CHOP (rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisone) may reduce the negative prognostic significance of the non-GCB (germinal center B-cell) phenotype in patients with newly diagnosed diffuse large B-ce